Antitumor Mechanisms of Immune Checkpoints PD-L1/PD-1 Blockade in Cancer Treatment
نویسندگان
چکیده
Programmed death-1 (PD-1) and its ligand (programmed death ligand 1, PD-L1) are negative regulators of immunity. They play a negative role in regulating immune response through interacting with immune cells, resulting in inhibited antitumor response. Tumor immunotherapy with PD-1 or PD-L1 antibody has been shown to be capable of prolonging survival of cancer patients and improving their life quality. Here we summarize the role of PD-L1/PD-1 in regulating immune response, antitumor mechanism and application of PD-L1/PD-1 blockade in cancer treatment.
منابع مشابه
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade...
متن کاملPD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
PD-1-PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1-PD-L1 axis is affected by the complex immunologic regulation network, and some CD8+ T cells can enter an irreversible dysfunctional state that cannot be rescued by PD-1/PD-L1 blockade. In most advanced cancers, except Hod...
متن کاملFunctional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, and avelumab. These therapies, referred to here as PD-L1/PD-1 checkpoint blockade therapies, are de...
متن کاملMechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies
Immune checkpoint blockade therapeutics, notably antibodies targeting the programmed death 1 (PD-1) receptor and its PD-L1 and PD-L2 ligands, are currently revolutionizing the treatment of cancer. For a sizeable fraction of patients with melanoma, lung, kidney and several other solid cancers, monoclonal antibodies that neutralize the interactions of the PD-1/PD-L1 complex allow the reconstituti...
متن کاملStructural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Cancer cells express tumour-specific antigens derived via genetic and epigenetic alterations, which may be targeted by T-cell-mediated immune responses. However, cancer cells can avoid immune surveillance by suppressing immunity through activation of specific inhibitory signalling pathways, referred to as immune checkpoints. In recent years, the blockade of checkpoint molecules such as PD-1, PD...
متن کامل